298 related articles for article (PubMed ID: 25653554)
1. Cardiac risk in the treatment of breast cancer: assessment and management.
Valachis A; Nilsson C
Breast Cancer (Dove Med Press); 2015; 7():21-35. PubMed ID: 25653554
[TBL] [Abstract][Full Text] [Related]
2. Cardiac effects of adjuvant therapy for early breast cancer.
Theodoulou M; Seidman AD
Semin Oncol; 2003 Dec; 30(6):730-9. PubMed ID: 14663774
[TBL] [Abstract][Full Text] [Related]
3. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems.
Bird BR; Swain SM
Clin Cancer Res; 2008 Jan; 14(1):14-24. PubMed ID: 18172247
[TBL] [Abstract][Full Text] [Related]
4. Management of febrile neutropenia and cardiac toxicity in the adjuvant treatment of breast cancer.
O'Shaughnessy JA
Clin Breast Cancer; 2007 Dec; 8 Suppl 1():S11-21. PubMed ID: 18282366
[TBL] [Abstract][Full Text] [Related]
5. Is it safe to give anthracyclines concurrently with trastuzumab in neo-adjuvant or metastatic settings for HER2-positive breast cancer? A meta-analysis of randomized controlled trials.
Du F; Yuan P; Zhu W; Wang J; Ma F; Fan Y; Xu B
Med Oncol; 2014 Dec; 31(12):340. PubMed ID: 25416049
[TBL] [Abstract][Full Text] [Related]
6. Principles of a risk evaluation and mitigation strategy (REMS) for breast cancer patients receiving potentially cardiotoxic adjuvant treatments.
Ahmed SH; Moussa Sherif DE; Fouad Y; Kelany M; Abdel-Rahman O
Expert Opin Drug Saf; 2016 Jul; 15(7):911-23. PubMed ID: 27007468
[TBL] [Abstract][Full Text] [Related]
7. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects.
Carver JR; Shapiro CL; Ng A; Jacobs L; Schwartz C; Virgo KS; Hagerty KL; Somerfield MR; Vaughn DJ;
J Clin Oncol; 2007 Sep; 25(25):3991-4008. PubMed ID: 17577017
[TBL] [Abstract][Full Text] [Related]
8. Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium.
Lamot C; Rottey S; De Backer T; Van Bortel L; Robays H; Van Belle S; Denys H; Cocquyt V
Acta Clin Belg; 2010; 65(5):300-4. PubMed ID: 21128555
[TBL] [Abstract][Full Text] [Related]
9. [Towards an integrated approach to cardiovascular toxicities related to the treatments of breast cancer].
Tanz R; Magne N; Annede P; Mery B; Jacob J; Bauduceau O; Trone JC; Guichard JB; Meillan N; Kirova Y; Vedrine L; Chargari C
Bull Cancer; 2014; 101(7-8):730-40. PubMed ID: 25091656
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
11. Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer.
Towns K; Bedard PL; Verma S
Curr Oncol; 2008 Jan; 15(Suppl 1):S16-29. PubMed ID: 18231644
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab-related cardiac events in the treatment of early breast cancer.
Fried G; Regev T; Moskovitz M
Breast Cancer Res Treat; 2013 Nov; 142(1):1-7. PubMed ID: 24154507
[TBL] [Abstract][Full Text] [Related]
13. Ongoing adjuvant trials with trastuzumab in breast cancer.
Tan AR; Swain SM
Semin Oncol; 2003 Oct; 30(5 Suppl 16):54-64. PubMed ID: 14613027
[TBL] [Abstract][Full Text] [Related]
14. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
[TBL] [Abstract][Full Text] [Related]
15. Use of non-anthracycline regimens in early stage breast cancer in Australia.
de Boer RH; Chan A; Tran B; Wilcken N
Asia Pac J Clin Oncol; 2011 Mar; 7(1):4-10. PubMed ID: 21332644
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Anthracyclines in Breast Cancer: What Is Their Role?
Shah AN; Gradishar WJ
Oncologist; 2018 Oct; 23(10):1153-1161. PubMed ID: 30120159
[TBL] [Abstract][Full Text] [Related]
17. Integrating bevacizumab into the treatment of patients with early-stage breast cancer: focus on cardiac safety.
Yardley DA
Clin Breast Cancer; 2010 Apr; 10(2):119-29. PubMed ID: 20353933
[TBL] [Abstract][Full Text] [Related]
18. Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab.
Cao L; Cai G; Chang C; Yang ZZ; Feng Y; Yu XL; Ma JL; Wu J; Guo XM; Chen JY
Oncotarget; 2016 Jan; 7(1):1042-54. PubMed ID: 26460956
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2.
Ganz PA; Romond EH; Cecchini RS; Rastogi P; Geyer CE; Swain SM; Jeong JH; Fehrenbacher L; Gross HM; Brufsky AM; Flynn PJ; Wahl TA; Seay TE; Wade JL; Biggs DD; Atkins JN; Polikoff J; Zapas JL; Mamounas EP; Wolmark N
J Clin Oncol; 2017 Dec; 35(35):3942-3948. PubMed ID: 29072977
[TBL] [Abstract][Full Text] [Related]
20. SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab.
Meattini I; Curigliano G; Terziani F; Becherini C; Airoldi M; Allegrini G; Amoroso D; Barni S; Bengala C; Guarneri V; Marchetti P; Martella F; Piovano P; Vannini A; Desideri I; Tarquini R; Galanti G; Barletta G; Livi L
Med Oncol; 2017 May; 34(5):75. PubMed ID: 28364270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
